Gyre highlights R&D pipeline progress for degraders and DACs
Gyre says its pipeline of targeted protein degraders and DACs targets unmet needs in oncology, immunology and fibrosis. The company points to China commercial revenues supporting global R&D and cites F351 and ETUARY™ for its fibrosis franchise.
A diversified pipeline of targeted protein degraders and DACs addresses major unmet needs in oncology, immunology, and fibrosis.
Commercial revenues from China support global R&D, with F351 and ETUARY™ anchoring the fibrosis franchise and multiple assets advancing toward key clinical milestones.Ori…